CorVue Approval Status
- FDA approved: No
- Brand name: CorVue
- Generic name: binodenoson
- Company: King Pharmaceuticals, Inc.
- Treatment for: Diagnosis and Investigation
CorVue (binodenoson) is an investigational cardiac pharmacologic stress SPECT (single-photon-emission computed tomographic) imaging agent intended for use in patients with or at risk for coronary artery disease (CAD) who are unable to perform a cardiac exercise stress test.
In October 2009, King Pharmaceuticals, Inc. announced the receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) advising the company that the New Drug Application (NDA) for CorVue (binodenoson) had not been approved.
Development Status and FDA Approval Process for CorVue
|Oct 21, 2009||FDA Issues Complete Response Letter for CorVue|
|Dec 19, 2008||King Pharmaceuticals Announces Submission of New Drug Application for CorVue|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.